Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)
Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low
platelet counts. The pathogenesis of ITP remains unclear although both antibody-mediated …
platelet counts. The pathogenesis of ITP remains unclear although both antibody-mediated …
Clinical updates in adult immune thrombocytopenia
MP Lambert, TB Gernsheimer - Blood, The Journal of the …, 2017 - ashpublications.org
Immune thrombocytopenia (ITP) occurs in 2 to 4/100 000 adults and results in variable
bleeding symptoms and thrombocytopenia. In the last decade, changes in our …
bleeding symptoms and thrombocytopenia. In the last decade, changes in our …
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia
AC Newland, B Sánchez‐González… - American journal of …, 2020 - Wiley Online Library
Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder,
characterized by a low platelet count (< 100× 109/L) in the absence of other causes …
characterized by a low platelet count (< 100× 109/L) in the absence of other causes …
Romiplostim or standard of care in patients with immune thrombocytopenia
DJ Kuter, M Rummel, R Boccia, BG Macik… - … England Journal of …, 2010 - Mass Medical Soc
Background Romiplostim, a thrombopoietin mimetic, increases platelet counts in patients
with immune thrombocytopenia, with few adverse effects. Methods In this open-label, 52 …
with immune thrombocytopenia, with few adverse effects. Methods In this open-label, 52 …
Immune thrombocytopenia
G Kistanguri, KR McCrae - Hematology/oncology clinics of …, 2013 - pmc.ncbi.nlm.nih.gov
Immune thrombocytopenia (ITP) is a common hematologic disorder characterized by
isolated thrombocytopenia. ITP presents as a primary form characterized by isolated …
isolated thrombocytopenia. ITP presents as a primary form characterized by isolated …
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment
The paradigm for managing primary immune thrombocytopenia (ITP) in adults has changed
with the advent of rituximab and thrombopoietin receptor agonists (TPO-RAs) as options for …
with the advent of rituximab and thrombopoietin receptor agonists (TPO-RAs) as options for …
Effect of severe sepsis on platelet count and their indices
Objectives: To examine platelet count and indices (mean platelet volume (MPV) and platelet
distribution width (PDW)) in severe sepsis. Methods: Patients with criteria for sepsis at a first …
distribution width (PDW)) in severe sepsis. Methods: Patients with criteria for sepsis at a first …
Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study
A Newland, B Godeau, V Priego… - British journal of …, 2016 - Wiley Online Library
In anecdotal reports, some patients with immune thrombocytopenia (ITP) maintained platelet
counts after discontinuing romiplostim. Here, we examined rates of platelet response (≥ 50× …
counts after discontinuing romiplostim. Here, we examined rates of platelet response (≥ 50× …
A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia
JB Bussel, GR Buchanan, DJ Nugent… - Blood, The Journal …, 2011 - ashpublications.org
Romiplostim, a thrombopoietin-mimetic peptibody, increases and maintains platelet counts
in adults with immune thrombocytopenia (ITP). In this first study of a thrombopoietic agent in …
in adults with immune thrombocytopenia (ITP). In this first study of a thrombopoietic agent in …
Is ITP a thrombophilic disorder?
F Rodeghiero - American Journal of Hematology, 2016 - Wiley Online Library
Immune thrombocytopenia (ITP) represents the epitome of acquired bleeding diseases for
the hematologist. Stemming from the interest for the safety of thrombopoietin‐receptor …
the hematologist. Stemming from the interest for the safety of thrombopoietin‐receptor …